Literature DB >> 16394329

Re-emergence of multi-drug resistant Shigella dysenteriae with added resistance to ciprofloxacin in north India & their plasmid profiles.

Neelam Taneja1, Valarie Lyngdoh, Archa Vermani, Balwinder Mohan, Pooja Rao, Malkit Singh, Ashok Dogra, Mini P Singh, Meera Sharma.   

Abstract

BACKGROUND &
OBJECTIVES: Multi drug resistant Shigellae pose a major threat in control of shigellosis with. Shigella dysenteriae being the most prevalent species at our centre before 1994. A gradual decrease in S. dysenteriae occurred over the years with a corresponding increase in S. flexneri which became the predominant serotype. From May to November 2003, an increase in number of patients admitted with clinical diagnosis of dysentery was noted in comparison to previous years, with a corresponding increase in the isolation of multi drug resistant S. dysenteriae. We report here the re-emergence of multi drug resistant S. dysenteriae at our tertiary care centre in north India after a gap of about 10 yr. Plasmid analysis of S. dysenteriae was also performed to study the origin and clonality of the isolates.
METHODS: Stool samples were collected in Cary-Blair medium and processed by standard methods. Shigellae were confirmed by serotyping. Minimum inhibitory concentration was done by agar dilution method and E-test. Plasmid profiling of 18 isolates (16 S. dysenteriae 1 and 2 S. dysenteriae 2) was performed by modified alkali lysis method. Clinical details of patients were noted.
RESULTS: A total of 64 patients with dysentery were admitted during the study period. Patients presented with unusually severe symptoms and six developed complications. Treatment failure with ciprofloxacin occurred in six patients who received cefotaxime and amikacin. There were 38 children below 5 yr of age. S. dysenteriae (18 isolates of S. dysenteriae 1 and 2 isolates of S. dysenteriae 2) were isolated from 20 of the 64 (31.2%) stool samples. S. dysenteriae re-emerged as the commonest isolate after a gap of nearly 10 yr. Fourteen of the 20 S. dysenteriae isolates were multi drug resistant; 12 were resistant to ciprofloxacin with MIC of 8-32 mug/ml. Plasmid profile analysis revealed that 6 of 11 ciprofloxacin resistant S. dysenteriae 1 had similar profiles. INTERPRETATION &
CONCLUSION: Emergence of a clone of ciprofloxacin resistant S. dysenteriae 1 in north India is disturbing as treatment options in our geographic area are limited in view of already existing high drug resistance to nalidixic acid, co-trimoxazole and amoxycillin. A close monitoring of shifts in serogroup distribution and antibiotic resistance is required to guide clinicians for treatment of shigellosis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16394329

Source DB:  PubMed          Journal:  Indian J Med Res        ISSN: 0971-5916            Impact factor:   2.375


  5 in total

1.  Changing epidemiology of shigellosis and emergence of ciprofloxacin-resistant Shigellae in India.

Authors:  Neelam Taneja
Journal:  J Clin Microbiol       Date:  2006-11-22       Impact factor: 5.948

2.  The Recent Trends of Shigellosis: A JIPMER Perspective.

Authors:  Jharna Mandal; Ganesh V; Jennifer Emelda; Mahadevan S; Subhash Chandra Parija
Journal:  J Clin Diagn Res       Date:  2012-11

3.  Enhanced resistance to fluoroquinolones in laboratory-grown mutants & clinical isolates of Shigella due to synergism between efflux pump expression & mutations in quinolone resistance determining region.

Authors:  Neelam Taneja; Arti Mishra; Ajay Kumar; Garima Verma; Meera Sharma
Journal:  Indian J Med Res       Date:  2015-01       Impact factor: 2.375

Review 4.  Shigellosis: Epidemiology in India.

Authors:  Neelam Taneja; Abhishek Mewara
Journal:  Indian J Med Res       Date:  2016-05       Impact factor: 2.375

5.  In silico analysis to identify vaccine candidates common to multiple serotypes of Shigella and evaluation of their immunogenicity.

Authors:  Sapna Pahil; Neelam Taneja; Hifzur Rahman Ansari; G P S Raghava
Journal:  PLoS One       Date:  2017-08-02       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.